Aditxt, Inc. filings document the company’s life sciences platform, its common stock capital structure, and material events affecting its operating subsidiaries and public-company status. Recent Form 8-K reports cover the completed acquisition of Ignite Proteomics, related financial statements and pro forma information, senior unsecured promissory notes, at-the-market offering capacity, and Nasdaq listing-compliance matters.
Proxy materials and meeting reports describe board elections, auditor ratification, executive-compensation votes, reverse stock split authority, and other stockholder matters. The filing record also includes disclosures on preferred stock issued in acquisition consideration, equity financing arrangements, governance approvals, and risks associated with maintaining exchange listing standards.
Aditxt, Inc. (ADTX) disclosed that its wholly owned subsidiary Ignite Proteomics, LLC and Copley Acquisition Corp. mutually terminated their Business Combination Agreement, effective immediately on October 9, 2026.
The related ancillary documents, including the Seller Support Agreements, Insider Letter Amendment and Lock-Up Agreements, terminated at the same time. Each party will bear its own expenses, and the agreement provides mutual releases for claims relating to the business combination, except claims under the Termination Agreement. Specified provisions of the Business Combination Agreement survive.
Aditxt, Inc. (ADTX) common stock is the subject of a Form 25 notification by Nasdaq Stock Market LLC to remove the class from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq states it complied with its rules to strike the class from listing and/or withdraw its registration.
Aditxt, Inc. (ADTX) disclosed that Nasdaq announced it will file a Form 25 with the SEC to complete the delisting of Aditxt common stock. The delisting becomes effective ten days after the Form 25 filing.
Trading on Nasdaq has been suspended since June 25, 2026, after the Nasdaq Hearings Panel denied Aditxt’s request to continue listing. The common stock is currently quoted on the OTC Market.
Aditxt, Inc. (ADTX) reported that on August 12, 2026 it entered into a Stock Purchase Agreement under which MDNA Holdings Inc. acquired substantially all of the outstanding shares of Aditxt’s majority‑owned subsidiary, Pearsanta, Inc. The buyer assumed Pearsanta liabilities reflected, reserved against or specifically disclosed in the closing statement, excluding intercompany balances between Aditxt and Pearsanta and any liabilities expressly retained by Aditxt. As additional consideration, Pearsanta agreed to pay Aditxt a 2.5% royalty on Net Revenue starting from the first commercial sale of any Pearsanta product or service and continuing until the earlier of ten years or aggregate royalties of $2,500,000. Pearsanta will also make milestone payments to Aditxt of $250,000 after completing a financing of at least $10,000,000 and $250,000 following an IPO, reverse merger, merger, acquisition, change of control or sale of substantially all of Pearsanta’s assets.
Aditxt, Inc. entered into Amendment No. 2 to its Note Purchase Agreement on July 16, 2026, with its wholly owned subsidiary Ignite Proteomics LLC and the investors. The amendment admits a new investor, cancels one previously issued senior secured note and provides for the issuance of two Additional Notes.
The cancelled note's original principal equals the aggregate original principal of the two Additional Notes, so the total original principal of senior secured notes under the agreement does not change. These notes are secured by substantially all assets of Ignite under a Security Agreement and by a pledge of all Ignite equity held by Aditxt. The Additional Notes were sold in an unregistered offering relying on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, with each investor representing accredited status and investment intent.
Aditxt, Inc. reports an amendment filing showing Christopher Castillo beneficially owns 62,000 shares of Common Stock. The filing states the shares represent 6.2% of the class and that Mr. Castillo has sole voting and dispositive power over 62,000 shares. The filing is signed on 07/02/2026.
Aditxt, Inc. reports that Christopher Castillo beneficially owns 75,000 shares of Common Stock, representing 9.19% of the class as disclosed on the filing. The filing lists CUSIP 007025869 and gives an address for the reporting person; the signature date is 07/02/2026.
Aditxt, Inc. Schedule 13G: Jerzy Stanislaw Wojcik reports beneficial ownership of 160,144 shares of Common Stock, representing 19,6 %, as of 06/11/2026. The filing shows Mr. Wojcik has sole voting and sole dispositive power over all 160,144 shares. The form lists the issuer's principal executive office in Richmond, Virginia, and provides CUSIP 007025869.
Aditxt, Inc. disclosed that Takeover Time 2026 LLC, a ten percent owner, completed an open-market sale of 3,420,439 shares of common stock at $0.02 per share. After this transaction, the reporting holder no longer owned any Aditxt common shares according to the filing.
Takeover Time 2026 LLC, an investment entity managed by Natasha Ovsepyan, disclosed that it sold 3,420,439 shares of Aditxt, Inc. common stock in open market and brokerage transactions on June 23, 2026. After this sale, it reports beneficial ownership of 0 shares, or 0.0% of Aditxt’s outstanding common stock. The filing notes that its original position was purchased with working capital and that it now has no contracts or arrangements relating to Aditxt securities.